The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 7, 2005, Pages 605-611

  Gilissen, L P L ^a   Bierau, J ^a   Derijks, L J J ^b   Bos, L P ^c   Hooymans, P M ^c   Van Gennip, A ^a   Stockbrugger R W ^a   Engels, L G J B ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; GENOTYPE; HUMAN; IN VIVO STUDY; LABORATORY TEST; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PROSPECTIVE STUDIES; THIOGUANINE;

EID: 26244455766     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02630.x     Document Type: Article

References (30)

1. Feagan BG, Sandborn WJ. Initial therapy for mild to moderate Crohn's disease: mesalamine or budenoside? Rev Gastroenterol Disord 2002; 2 (Suppl. 2): S9-15.
2. Nikolaus S, Folscn U, Schreiber S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000; 47: 71-82.
3. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003; 3: CD000543.
4. Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002; 4: CD000544.
5. Cama C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465-73.
6. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118: 264-73.
7. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2: 379-88.
8. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35.
9. Sumi S, Marinaki A, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111: 360-7.
10. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-7.
11. Zelinkova Z, Derijks L, Stokkers P, et al. Inosine Triphosphate Pyrophosphatase Gene Mutation Predicts Myelosuppression in IBD Patients treated with Azathioprine. New Orleans, LA, USA: Abstract Book Digestive Disease Week, 2004: A166 (no. 812).
12. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
13. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomic and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
14. Roblin X, Serre-Debeaubais F, Phelip JM, et al 6-Tioguanine monitoring in steroid dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005; 21: 829-39.
15. Cuffari C, Hunt S, Bayless T. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009-14.
16. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
17. Gupta P, Gokhale R, Kirschner B. 6-Mercaptopurine (6MP) metabolite levels in children with IBD. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.
18. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
19. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14: 407-17.
20. Black AJ, McLeod HL, Capell HA. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-8.
21. Lennard L. Clinical implications of thiopurine methyltransferase - optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527-31.
22. Derijks LJJ, Gilissen LPL, Engels LGJB, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease; implications for therapy. Ther Drug Monit 2004; 26: 311-8.
23. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Pharmacol 1996; 49: 393-6.
24. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-9.
25. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464-75.
26. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut 2001; 49: 656-64.
27. Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002; 16: 79-85.
28. Xin H, Fischer C, Schwab M, Klotz U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 1105-9.
29. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 4947: 1041-8.
30. Jacques-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994; 38: 1-8.